Organogenesis Holdings Inc. director Michael Joseph Driscoll received an equity grant of 48,828 restricted stock units (RSUs) of Class A common stock. This compensation-related acquisition, granted at no cash cost, will vest in full on February 15, 2027. Following the grant, Driscoll’s direct Class A share balance stands at 215,707 shares.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Equity grant gives Organogenesis (ORGO) director 48,828 RSUs vesting 2027
Organogenesis Holdings Inc. director Michael Joseph Driscoll received an equity grant of 48,828 restricted stock units (RSUs) of Class A common stock. This compensation-related acquisition, granted at no cash cost, will vest in full on February 15, 2027. Following the grant, Driscoll’s direct Class A share balance stands at 215,707 shares.